{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:46:10Z","timestamp":1781196370176,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":569,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cmi.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T02:20:17Z","timestamp":1644459617000},"page":"1345-1350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients"],"prefix":"10.1016","volume":"28","author":[{"given":"Madeleine R.","family":"Heldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja M.","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.02.001_bib1","first-page":"149","article-title":"Herpesvirus evasion of the immune system","volume":"232","author":"Johnson","year":"1998","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.cmi.2022.02.001_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","article-title":"Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies","volume":"23","author":"Sahoo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.02.001_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coviro.2014.09.006","article-title":"Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials","volume":"9","author":"Hill","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cmi.2022.02.001_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/cid\/ciaa222","article-title":"High incidence of herpes zoster after cord blood hematopoietic cell transplant despite longer duration of antiviral prophylaxis","volume":"72","author":"Xue","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib5","series-title":"Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016","first-page":"1","author":"McQuillan","year":"2018"},{"key":"10.1016\/j.cmi.2022.02.001_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13526","article-title":"Herpes simplex virus infections in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Lee","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2022.02.001_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.02.001_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM198603133141105","article-title":"Infections with herpes simplex viruses (1)","volume":"314","author":"Corey","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.02.001_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.coviro.2013.04.004","article-title":"T-cell immunity to human alphaherpesviruses","volume":"3","author":"Ouwendijk","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cmi.2022.02.001_bib10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4049\/jimmunol.179.1.322","article-title":"Psychological stress compromises CD8+ T cell control of latent herpes simplex virus type 1 infections","volume":"179","author":"Freeman","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2022.02.001_bib11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/infdis\/140.4.487","article-title":"Identification of patients with increased risk of infection with herpes simplex virus after renal transplantation","volume":"140","author":"Pass","year":"1979","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/infdis\/156.2.280","article-title":"A\u00a0comparative study of herpes simplex infections in renal transplant and leukemic patients","volume":"156","author":"Greenberg","year":"1987","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1056\/NEJM198107093050202","article-title":"Acyclovir prophylaxis of herpes-simplex-virus infections","volume":"305","author":"Saral","year":"1981","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.02.001_bib14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1086\/315524","article-title":"Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance","volume":"181","author":"Chakrabarti","year":"2000","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood.V99.3.1085","article-title":"Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation","volume":"99","author":"Langston","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.02.001_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.02.001_bib17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1056\/NEJM199105023241804","article-title":"Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor","volume":"324","author":"Brown","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.02.001_bib18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/cid\/cir610","article-title":"Severe viral infections and primary immunodeficiencies","volume":"53","author":"Dropulic","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1089\/vim.2017.0136","article-title":"Varicella virus vaccination in the United States","volume":"31","author":"Shaw","year":"2018","journal-title":"Viral Immunol"},{"key":"10.1016\/j.cmi.2022.02.001_bib20","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/ajt.16534","article-title":"Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients","volume":"21","author":"Hirzel","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2022.02.001_bib21","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: a systematic review","volume":"71","author":"McKay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/j.pain.0000000000000307","article-title":"A\u00a0systematic review and meta-analysis of risk factors for postherpetic neuralgia","volume":"157","author":"Forbes","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.cmi.2022.02.001_bib23","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.cmi.2022.02.001_bib24","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.02.001_bib25","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3324\/haematol.2019.223073","article-title":"Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation","volume":"104","author":"Ward","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2022.02.001_bib26","first-page":"1","article-title":"Prevalence of antibodies to human herpesviruses 6 and 7 in early infancy and age at primary infection","volume":"19","author":"Cermelli","year":"1996","journal-title":"New Microbiol"},{"key":"10.1016\/j.cmi.2022.02.001_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/TP.0000000000000306","article-title":"Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: a randomized clinical trial","volume":"99","author":"Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2022.02.001_bib28","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2018.01454","article-title":"Advances in the characterization of the T-cell response to human herpesvirus-6","volume":"9","author":"Hanson","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2022.02.001_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clim.2013.02.023","article-title":"Increased proportion of perforin-expressing CD8+T-cells indicates control of herpesvirus reactivation in children after stem cell transplantation","volume":"148","author":"de Pagter","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cmi.2022.02.001_bib30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/infdis\/jiaa422","article-title":"Donor-derived CD4+ T cells and human herpesvirus 6B detection after allogeneic hematopoietic cell transplantation","volume":"223","author":"Hanson","year":"2021","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib31","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.TP.0000145989.22373.03","article-title":"Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis","volume":"78","author":"Limaye","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2022.02.001_bib32","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.02.001_bib33","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/bloodadvances.2021004362","article-title":"Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients","volume":"5","author":"Hill","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2022.02.001_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.02.001_bib35","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2005-09-3624","article-title":"Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2014a randomized double-blind placebo-controlled study","volume":"107","author":"Boeckh","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.02.001_bib36","first-page":"185","article-title":"Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in\u00a0vitro","volume":"1","author":"Ljungman","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.02.001_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/(SICI)1096-9071(199709)53:1<63::AID-JMV11>3.0.CO;2-Y","article-title":"Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization","volume":"53","author":"Haumont","year":"1997","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2022.02.001_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008609","article-title":"Tetrameric glycoprotein complex gH\/gL\/gQ1\/gQ2 is a promising vaccine candidate for human herpesvirus 6B","volume":"16","author":"Wang","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2022.02.001_bib39","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T\u2014and a side order of IgG, to go?\u2014immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.cmi.2022.02.001_bib40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.blre.2017.09.003","article-title":"Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation","volume":"32","author":"Ueda","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.cmi.2022.02.001_bib41","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.bmt.1704959","article-title":"The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation","volume":"35","author":"Thomson","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.02.001_bib42","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2022.02.001_bib43","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib44","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A\u00a0prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2022.02.001_bib45","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.02.001_bib46","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A\u00a0vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.02.001_bib47","series-title":"UFaD","year":"2021"},{"key":"10.1016\/j.cmi.2022.02.001_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.02.001_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib51","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 Years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib52","doi-asserted-by":"crossref","first-page":"ofaa172","DOI":"10.1093\/ofid\/ofaa172","article-title":"Immunogenicity of inactivated varicella zoster vaccine in autologous hematopoietic stem cell transplant recipients and patients with solid or hematologic cancer","volume":"7","author":"Boeckh","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib53","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/bloodadvances.2020002269","article-title":"Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study","volume":"4","author":"Camargo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2022.02.001_bib54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/infdis\/147.4.737","article-title":"Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella","volume":"147","author":"Zaia","year":"1983","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.001_bib55","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.cmi.2022.02.001_bib56","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2022.02.001_bib57","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2022.02.001_bib58","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jha2.175","article-title":"Patient risk stratification and tailored clinical management of post-transplant CMV-, EBV-, and BKV-infections by monitoring virus-specific T-cell immunity","volume":"2","author":"Papadopoulou","year":"2021","journal-title":"eJHaem"},{"key":"10.1016\/j.cmi.2022.02.001_bib59","series-title":"high-risk patients after allogeneic hematopoietic cell transplant","article-title":"Phase 2 multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of Viralym-M compared to placebo for the prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV infection and\/or disease","year":"2021"},{"key":"10.1016\/j.cmi.2022.02.001_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcyt.2016.09.013","article-title":"Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy","volume":"19","author":"Ma","year":"2017","journal-title":"Cytotherapy"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:32:13Z","timestamp":1761118333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2200057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1198743X2200057X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.02.001","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}